Начало・Списък с акции・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Отворен

33.25 1.31

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

31.75

Максимум

33.81

Ключови измерители
By Trading Economics
Приходи	43M 13M
Продажби	29M 107M
EPS	0.25
Марж на печалбата	12.139
Служители	524
EBITDA	25M 17M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+112.53% upside

Дивиденти
By Acuity
Следващи печалби	6.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	200M 1.6B
Предишно отваряне	31.94
Предишно затваряне	33.25

Immunocore Holdings PLC ADR Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

5.08.2026 г., 20:02 ч. UTC

Immunocore Holdings PLC is higher today, reflecting broader gains in the Biotechnology sector. No specific company news was identified to explain the movement.

4.08.2026 г., 19:51 ч. UTC

Immunocore Holdings PLC shares are higher today amid broader market strength and a notable decline in crude oil prices, easing inflation concerns.

3.08.2026 г., 20:03 ч. UTC

News

Immunocore Holdings PLC is declining in Monday's session, diverging from gains in major tech stocks and remaining below its 20-day moving average.

31.07.2026 г., 20:06 ч. UTC

Immunocore Holdings PLC shares are lower today, with no specific news identified. The stock has fluctuated within a routine range during the session.

28.07.2026 г., 19:56 ч. UTC

Immunocore Holdings PLC shares are lower today, continuing a three-session decline amid broader market sentiment influenced by declines in Asian markets.

27.07.2026 г., 18:06 ч. UTC

Immunocore Holdings PLC shares are lower today, reflecting a broader market trend amid a significant decline in oil prices. No specific company news was identified.

24.07.2026 г., 15:26 ч. UTC

Immunocore Holdings PLC shares are lower today, having declined from a session high. This movement occurs amid mixed labor market data and inflation concerns.

22.07.2026 г., 19:16 ч. UTC

News

Immunocore Holdings PLC shares are higher as Wall Street Zen upgraded its rating to "buy," despite a mixed analyst outlook.

21.07.2026 г., 21:01 ч. UTC

Immunocore Holdings PLC shares are higher in after-market trading, driven by optimistic sentiment in U.S. markets and better-than-expected results from major companies.

20.07.2026 г., 20:06 ч. UTC

News

Immunocore Holdings PLC shares are lower amid broader market weakness. Analyst ratings show mixed sentiment, with upgrades and downgrades influencing performance.

Сравнение с други в отрасъла

Ценова промяна

Immunocore Holdings PLC ADR Прогноза

Ценова цел

By TipRanks

112.53% нагоре

12-месечна прогноза

Среден 70.75 USD 112.53%

Висок 100 USD

Нисък 35 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Immunocore Holdings PLC ADR през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

4 ratings

Купи

Задържане

Продай

Според 4 анализатори, дали борсови рейтинги на Immunocore Holdings PLC ADR през последните 3 месеца.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.